Revlimid_BPA
Special Notice Posted
- Solicitation number
- 36C77026A0003
- Set-aside
- 8(a) Sole Source
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
- Points of contact
-
- Justin Braden Smith justin.smith1@va.gov
- Kelley Cunningham kelley.cunningham@gmail.com (913) 684-0140
Notice details come from SAM.gov. Updated .
About this opportunity
This Special Notice constitutes an award notice for a national Blanket Purchase Agreement (BPA) issued by the Department of Veterans Affairs, Network Contracting Office 15 (NCO 15) in Leavenworth, Kansas. The award, designated 36C77026A0003, was made to Bristol-Myers Squibb Company on February 5, 2026, for the supply of Revlimid (lenalidomide) capsules. This is a sole-source procurement under the 8(a) set-aside authority, with the contract structured off Bristol-Myers Squibb's existing GSA Federal Supply Schedule contract. The award covers pharmaceutical preparations under Product Service Code 6505 and NAICS Code 325412 (pharmaceutical preparation manufacturing). The Special Notice was published on February 6, 2026, and represents a completed award rather than an open solicitation for competitive bidding.
The BPA was established to ensure VA-wide utilization of brand-name Revlimid across multiple Veterans Integrated Service Networks (VISNs) for a 12-month ordering period from February 2, 2026 through February 1, 2027, with no option periods. The VA determined that only Bristol-Myers Squibb could meet the agency's requirements due to the product's compliance with the Risk Evaluation and Mitigation Strategy (REMS) restricted distribution program and the fact that certain patient populations cannot tolerate generic lenalidomide formulations due to ingredient intolerance or hypersensitivity. Market research conducted January 27-28, 2026 confirmed no small-business alternatives existed that could satisfy REMS requirements and support VISN-wide utilization. The procurement was declared an emergency to ensure continuity of medical treatment for cancer patients. The justification for sole-source authority was approved through multiple levels, including the Contracting Officer, Director of Contracting, and VHA Head of Contracting Activity, with the contract value requiring higher-level approval in the $750,000 to $75 million threshold range. This award notice is final and will be archived 60 days after the award date.
Notice text
AWARD NOTICE - BPA -
JnA - Revlimid - BPA
Files
| File | Type | Posted |
|---|---|---|
| 36C77026A0003_1.pdf | ||
| P03_JnA_Revlimid_DOC signed_updated_HCA__Redacted_.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity